Please assess the completion status of the following clinical trial:

Trial Title: A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of~EITHER acute first onset transverse myelitis (using the TM Consortium Working Group 2002 criteria) - patients must fulfill all of the following criteria:~* Sensory, motor, or autonomic dysfunction attributable to spinal cord disease~* Bilateral signs and/or symptoms (not necessarily symmetric)~* Sensory level (except in young children \<5 years where this is difficult to evaluate)~* Lack of MRI brain criteria consistent with multiple sclerosis~* Progression to nadir between 4 h and 21 days~OR first presentation of neuromyelitis optica (using standardised criteria) - patients must fulfil both absolute criteria:~* Optic neuritis~* Acute myelitis, plus two out of three supportive criteria (as Aquaporin 4 antibody (AQP4) is often not available acutely, only the first two supportive criteria would be applied),~* Brain MRI not meeting criteria for Multiple Sclerosis (MS) at disease onset~* Spinal cord MRI with contiguous T2-weighted signal abnormality extending over three or more vertebral segments, indicating a relatively large lesion in the spinal cord~* AQP4 seropositive status~  * ASIA Impairment Score of A-C~ * Randomisation to occur no later than day 5 of steroids, and, if definitely known, within 21 days from symptom onset.~ * Give assent (8-16 years)/consent to participate in the trial~Exclusion Criteria:~* Contraindication to IVIG as stated in the summary of product characteristics (SmPC), or receiving IVIG for other reasons~* Previously known systemic autoimmune disease (e.g. systemic lupus erythematosus) or any evidence of systemic inflammation during current presentation.~* Direct infectious aetiology (e.g. varicella zoster)~* Previous episode of central nervous system (CNS) inflammatory demyelination~* Acute disseminated encephalomyelitis (ADEM)~* Other causes of myelopathy not thought to be due to myelitis (e.g. nutritional, ischaemic, tumour etc.)~* Other disease which would interfere with assessment of outcome measures~* Known pregnancy~* Circumstances which would prevent follow-up for 12 month

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous Methylprednisolone (Type: ACTIVE_COMPARATOR): Paediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days.
- Intravenous Immunoglobulin (Type: EXPERIMENTAL): Paediatric patients \<41.2kg - total dose of 2g/kg in divided doses over 2 days.~All other patients - total dose of 2g/kg in divided doses over 5 days.~PLUS Intravenous Methylprednisolone~Pediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).